Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. The call provides investors with an opportunity to hear management discuss the company's progress in developing therapies for gastrointestinal and rare diseases, including the advancement of apraglutide for short bowel syndrome.

Call Details

Individuals interested in participating in the live call can dial (888) 596-4144 for U.S. participants or (646) 968-2525 for international participants. The conference ID number and event passcode is 3647053. A live webcast will also be accessible via the Investors & Media section of Ironwood’s website at www.ironwoodpharma.com .

Replay Information

The conference call will be available for replay via telephone starting Thursday, August 6, 2026, at approximately 11:30 a.m. Eastern Time. The replay will remain available through 11:59 p.m. Eastern Time on Thursday, August 20, 2026. To listen to the telephone replay, dial (800) 770-2030 (U.S. and Canada) using conference ID number 3647053. Following the call, a replay of the webcast will be posted on the Investors & Media section of the Company’s website.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for people living with gastrointestinal (GI) and rare diseases. Founded in 1998, the company is headquartered in Boston, Massachusetts, with an additional site in Basel, Switzerland.

Key developments include:

• Apraglutide: A next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support.
• LINZESS (linaclotide): The U.S. branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

For further information, investors can visit http://www.ironwoodpharma.com or follow the company on X and LinkedIn.

Ironwood Pharmaceuticals, Inc. announced the appointment of Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, succeeding Dr. Michael Shetzline. Dr. Silber will oversee Research and Drug Development, Regulatory Affairs, and Medical Affairs, reporting to Chief Executive Officer Tom McCourt. The leadership transition comes as the company advances its pipeline of therapies for gastrointestinal and rare diseases.

Dr. Silber joins Ironwood on July 20, 2026, bringing extensive experience in drug development. Dr. Shetzline, who is retiring after a 30-year career, will remain an advisor to the company to ensure a seamless transition. The changes aim to strengthen the company's R&D strategy and execution capabilities.

Separately, Ironwood initiated the confirmatory Phase 3 STARS-2 trial of apraglutide in patients with short bowel syndrome with intestinal failure (SBS-IF) in June. The trial is now actively recruiting patients. Apraglutide is being developed as a potential treatment for SBS-IF, a rare and serious condition.

The STARS-2 trial is designed to confirm the efficacy and safety of apraglutide. The initiation of this trial marks a significant milestone in Ironwood's efforts to bring new therapies to patients with unmet medical needs. The company remains focused on advancing its pipeline and delivering life-changing treatments.

Key Leadership Changes